{"entity":{"id":"immunopeptidome","kind":"term","name":"Immunopeptidome","aka":["HLA ligandome","HLA peptidome"],"tldr":"The immunopeptidome is the collection of peptides associated with immune display molecules in a particular biological setting. A measurement recovers a view of that collection through a defined assay.","summary":"An immunopeptidome concerns displayed peptide ligands, rather than every protein or RNA message in a sample. Direct analysis of native melanoma tissue identified HLA-associated peptides, including some containing tumor mutations. What is recovered depends on the tissue and analytical workflow. The observed collection should retain its sample and method, and identifying a displayed peptide remains distinct from showing an immune response to it.","asOf":"2026-11-09","links":[{"label":"Direct identification of clinically relevant neoepitopes presented on native human melanoma tissue by mass spectrometry.","url":"https://doi.org/10.1038/ncomms13404"},{"label":"Primary evidence for the antigen-presentation teaching distinctions","url":"https://doi.org/10.1074/mcp.tir117.000383"},{"label":"Primary evidence for the antigen-presentation teaching distinctions","url":"https://doi.org/10.3389/fimmu.2019.00141"},{"label":"Primary evidence for the antigen-presentation teaching distinctions","url":"https://doi.org/10.1038/s41467-021-23713-9"},{"label":"Primary evidence for the antigen-presentation teaching distinctions","url":"https://doi.org/10.1038/s41587-019-0322-9"},{"label":"Primary evidence for the antigen-presentation teaching distinctions","url":"https://doi.org/10.1038/s41596-019-0133-y"}],"tags":[],"related":["immunopeptidomics","binding-presentation-recognition","proteomics"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["The immunopeptidome is a biological repertoire in a defined cell population and context; an immunopeptidomics list is a method-dependent subset recovered and identified from a sample. Class I and class II repertoires are separate, and a protein can be abundant while a derived peptide is poorly generated, loaded or retained. Inflammatory signals changed peptide patterns in cancer cell lines (Chong et al., 2018, ovarian cancer cells and interferon gamma, PMID 29242379; Javitt et al., 2019, lung cancer cells and TNF-alpha and interferon gamma acting through HLA-B, PMID 30833945), which shows context-dependent remodelling and not that inflammation adds useful targets. Whole-lysate capture can recover intracellular as well as surface complexes, mixed tissue adds cancer, immune and stromal sources, relative instrument intensity is not surface copies per cell, and a reported sequence can be misassigned (Wilhelm et al., 2021, PMID 34099720). Method B identifying 1,200 peptides against method A's 800 (fictional) shows no biological difference. Sarkizova et al. (2020) gives allele-dependent repertoires from mono-allelic lines."],"category":"Immunology"},"route":"/terms/immunopeptidome/","neighbours":{"term":[{"id":"immune-product-evidence","kind":"term","name":"Immune measurements and product evidence","route":"/terms/immune-product-evidence/"},{"id":"immunopeptidomics","kind":"term","name":"Immunopeptidomics","route":"/terms/immunopeptidomics/"},{"id":"binding-presentation-recognition","kind":"term","name":"Peptide binding, presentation and immune recognition","route":"/terms/binding-presentation-recognition/"}],"technology":[{"id":"proteomics","kind":"technology","name":"Proteomics & phosphoproteomics","route":"/technologies/proteomics/"}],"pathway":[{"id":"antigen-presentation-immunoediting","kind":"pathway","name":"Antigen presentation & immune editing","route":"/pathways/antigen-presentation-immunoediting/"}]}}